GRI Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by GRI Bio, Inc. on January 28, 2026. The Company is a biopharmaceutical entity incorporated in Delaware, with its principal executive offices in La Jolla, California. The filing reports on a specific corporate event rather than a standard financial reporting period.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. As an 8-K reporting a specific event, the document does not provide a clear value for any financial metrics.
Material Changes
The material event reported is the issuance of a press release on January 28, 2026, announcing additional data from the Company's Phase 2a clinical trial. The trial investigates the investigational drug GRI-0621 in patients diagnosed with idiopathic pulmonary fibrosis (IPF). The full details of the data are contained in the attached press release (Exhibit 99.1).
Guidance, Outlook, and Risks
The filing incorporates the press release by reference but does not explicitly restate management's guidance, future outlook, or specific risk factors within the body of the 8-K text. The primary focus is the disclosure of the clinical trial update. No unusual items or contingencies are described in the filing text itself.
Investor Verification Checklist
- Review Exhibit 99.1 (the attached press release) for the specific clinical data results regarding GRI-0621.
- Verify the statistical significance and clinical relevance of the Phase 2a trial data for idiopathic pulmonary fibrosis.
- Check for any subsequent regulatory filings or updates regarding the trial's next steps or potential Phase 3 initiation.
- Confirm the Company's current cash runway and funding status in the most recent 10-Q or 10-K, as this 8-K does not provide liquidity details.